Why You Can't Sleep on Peptides
Your body has one rule it will not break during sleep: blood sugar cannot fall too low for too long.
When glucose drops below a certain threshold in the middle of the night, the brain reads that as a threat and activates what is called the counter-regulatory response, which is the body's emergency system for pulling blood sugar back up. The main tools it uses are cortisol and epinephrine, the same hormones that wake you up when something startles you. Cortisol triggers the liver to release stored glucose, epinephrine sharpens alertness, and together they do their job well. Your blood sugar comes back up. And you are wide awake at three in the morning wondering why you cannot sleep.
That is not a sleep disorder. That is a blood sugar rescue that worked exactly as designed.
Most people who start a peptide protocol and suddenly find themselves waking in the early hours assume they need melatonin or a better sleep stack, because the problem feels like a sleep problem. It is not. The mechanism is upstream of sleep entirely, which means fixing the sleep is the wrong target.
To understand why peptides are involved, you need a quick map of what the two main categories of peptides actually do to blood sugar.
The first category is incretin-based compounds like semaglutide, tirzepatide, and retatrutide. These drugs were designed to lower blood sugar and suppress appetite, and they do both extremely well. In the phase 2 trial on retatrutide published in the New England Journal of Medicine, participants at the 12mg dose lost an average of 24.2 percent of their body weight, and appetite suppression was documented across every dose group. When your appetite is that thoroughly blunted, it is easy to eat less than your body actually needs without feeling like you are restricting at all. You go to bed with less total fuel than usual, which means your liver has less stored glycogen to draw on, which means blood sugar has shorter runway before it starts to fall.
The second category is growth hormone secretagogues, compounds like CJC-1295, ipamorelin, and tesamorelin, which work by stimulating your pituitary gland to release pulses of growth hormone. The most common protocol is to inject before bed, because growth hormone naturally peaks during deep sleep and you want to amplify that pulse, not fight against it. The problem is that growth hormone is directly anti-insulin.
The mechanism for this is well established. Growth hormone increases the release of free fatty acids from fat tissue, and those free fatty acids compete with glucose for uptake in muscle and peripheral tissue, which is something called the glucose-fatty acid cycle. At the same time, GH reduces the liver's sensitivity to insulin directly, which pushes hepatic glucose production upward even when glucose is already available. Research from Moller and Jorgensen published in Endocrine Reviews documented that GH antagonizes both hepatic and peripheral insulin action through exactly this pathway.
The clinical consequence was demonstrated in a key study on the dawn phenomenon in Type 1 diabetes. When researchers used somatostatin to suppress nocturnal GH spikes, the dawn phenomenon disappeared. When they restored the GH spikes, it came back. Hepatic glucose production increased by approximately 30 percent in response to those GH pulses alone.
That 30 percent increase matters because it is not a smooth, stable rise. It creates a swing. Glucose goes up when GH fires, insulin tries to respond, and depending on how much fuel was available going into the night, the resulting drop on the back end of that swing can be enough to trigger the counter-regulatory alarm.
If you are taking an incretin and a GH secretagogue at the same time, both mechanisms are running simultaneously. Less stored fuel from undereating on the incretin, plus active blood sugar swings from the GH pulse, compound into a much more volatile night.
The fix depends on which mechanism is driving the problem.
If you are on an incretin and undereating, the answer is deliberate intake. Because your appetite signal is suppressed, you cannot rely on hunger to tell you when you have eaten enough. You have to track or structure your meals with enough protein, fat, and overall calories to give your body adequate glycogen stores going into sleep. If you are eating very low carbohydrate or ketogenic, this applies differently because the body adapts to use fat and ketones as primary fuel and maintains blood sugar through something called gluconeogenesis, which is the liver's ability to manufacture glucose from amino acids and glycerol. The issue is not the diet pattern. The issue is when an appetite-suppressing drug causes total intake to fall so low that even gluconeogenesis cannot keep pace.
If you are on a GH secretagogue, two adjustments are worth trying in combination. First, move your injection two to three hours earlier in the evening rather than immediately before bed, which shifts the timing of the GH pulse relative to your deepest sleep and gives blood sugar more time to stabilize before you are in the most vulnerable hours. Second, a small meal of protein and fat before bed, nothing large, just enough to give the liver substrate to work with, can blunt the depth of any nocturnal dip.
Both adjustments work on the same principle: give the body more buffer material so the counter-regulatory system never has to fire.
The larger lesson here is that peptides are not passive. They interact with hormonal systems that are already doing things at night, and those interactions have metabolic consequences that show up in ways that look nothing like what caused them. Waking at three in the morning looks like a sleep problem. It is actually your liver and your adrenal glands having a conversation about fuel. Understanding that your sleep quality is a downstream output of your metabolic stability during the night changes what you look at when something goes wrong, because the variable worth adjusting is almost never the sleep itself.
References
- Perriello G, De Feo P, Torlone E, et al. Nocturnal spikes of growth hormone secretion cause the dawn phenomenon in Type 1 diabetes mellitus by decreasing hepatic and extrahepatic sensitivity to insulin in the absence of insulin waning. Diabetologia. 1990;331:52-59. Finding: Suppressing nocturnal GH spikes with somatostatin abolished the dawn phenomenon; restoring GH spikes reproduced it. Hepatic glucose production increased approximately 30%. Source
- Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews. 2009;302:152-177. Finding: GH antagonizes insulin's hepatic and peripheral effects via increased free fatty acid flux and uptake. Source
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023;3896:514-526. Finding: 24.2% mean weight loss at 12mg dose; significant appetite suppression documented across all dose groups. Source
Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness
If this is the kind of information you want access to on a daily basis, the community is free and there are full courses on training, nutrition, hormones, and supplementation inside. You can ask questions and post your own labs and get feedback from me and from the community.